Dermavant Sciences to Present New ADORING Data on Tapinarof Cream for Atopic Dermatitis at 2024 AAD Annual Meeting
Dermavant Sciences, a biopharmaceutical company specializing in innovative therapies for immuno-dermatology, will unveil new ADORING data at the 2024 American Academy of Dermatology Annual Meeting. The data includes the treatment of patients with skin of color from Phase 3 trials of VTAMA® (tapinarof) cream, 1%, in adults and children aged 2 years and older with atopic dermatitis. This event will be held from March 8-12 in San Diego, California.
The VTAMA cream, an aryl hydrocarbon receptor agonist, is being developed as a once-daily, cosmetically elegant, and steroid-free topical cream for both acute treatment and long-term management of atopic dermatitis (AD). VTAMA cream, 1%, has current approval for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation under study in the ADORING Phase 3 development program for AD.
Several oral and poster presentations will be featured, highlighting key aspects of the ADORING trials:
- Tapinarof Cream 1% Once Daily in Adults and Children Down to 2 Years of Age with Moderate to Severe Atopic Dermatitis in Two Phase 3 Trials: Patient-reported Outcomes
- Presenter: Eric Simpson, MD, MCR
- This presentation will focus on patient-reported outcomes (PROs) including quality of life measures and assessment of AD symptoms for adults and children treated with tapinarof cream 1% once daily from the Phase 3 ADORING trials.
- Tapinarof Cream 1% Once Daily: Interim Analysis of ADORING 3 Phase 3 Long-term Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
- Presenter: Robert Bissonnette, MD
- This presentation will include data on the baseline characteristics of patients enrolling in ADORING 3, an open-label, long-term extension trial assessing the safety and efficacy of tapinarof cream 1% once daily for up to 48 weeks in adults and children with AD.
Additionally, two posters will present data on the efficacy and safety of tapinarof cream 1% once daily in adults and children with AD, focusing on patients with skin of color and the treatment’s tolerability across two pivotal Phase 3 trials.
